Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 271

1.

Biomarker development in the context of urologic cancers.

Kelloff GJ, Sigman CC, Scher HI.

Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Review.

PMID:
25746942
2.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

3.

Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.

Yoo SS, Jorgensen TJ, Kennedy AR, Boice JD Jr, Shapiro A, Hu TC, Moyer BR, Grace MB, Kelloff GJ, Fenech M, Prasanna PG, Coleman CN.

J Radiol Prot. 2014 Jun;34(2):R25-52. doi: 10.1088/0952-4746/34/2/R25. Epub 2014 Apr 14. Review.

PMID:
24727460
4.

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.

Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.

5.

Considerations in the development of circulating tumor cell technology for clinical use.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ.

J Transl Med. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138. Review.

6.

Cancer biomarkers: selecting the right drug for the right patient.

Kelloff GJ, Sigman CC.

Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14. doi: 10.1038/nrd3651. Review.

PMID:
22322254
7.

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee.

Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.

8.

A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC; Group.

Radiology. 2011 Mar;258(3):906-14. doi: 10.1148/radiol.10100799.

PMID:
21339352
9.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B.

Radiology. 2011 Jun;259(3):875-84. doi: 10.1148/radiol.10100800. Epub 2011 Feb 15.

PMID:
21325035
10.

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative.

Clin Cancer Res. 2010 Jul 1;16(13):3299-318. doi: 10.1158/1078-0432.CCR-10-0880. Epub 2010 May 25.

11.

Challenges in clinical prostate cancer: role of imaging.

Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group.

AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579.

12.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.

PMID:
19440188
13.

Early detection of oral neoplasia: watching with new eyes.

Kelloff GJ, Sigman CC, Contag CH.

Cancer Prev Res (Phila). 2009 May;2(5):405-8. doi: 10.1158/1940-6207.CAPR-09-0064. Epub 2009 Apr 28. Review. No abstract available.

14.

Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.

Eckelman WC, Reba RC, Kelloff GJ.

Drug Discov Today. 2008 Sep;13(17-18):748-59. doi: 10.1016/j.drudis.2008.05.009. Epub 2008 Jul 24. Review.

PMID:
18617011
15.

Regulatory and reimbursement challenges for molecular imaging.

Hoffman JM, Gambhir SS, Kelloff GJ.

Radiology. 2007 Dec;245(3):645-60.

PMID:
18024447
16.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
17.

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.

Kelloff GJ, Sigman CC.

Nat Rev Cancer. 2007 Jul;7(7):508-18. Review.

PMID:
17568791
18.

FDG-PET lymphoma demonstration project invitational workshop.

Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J.

Acad Radiol. 2007 Mar;14(3):330-9.

PMID:
17307666
19.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D.

Int J Radiat Biol. 2006 Oct;82(10):699-757. Review.

PMID:
17118889
20.

Chemoprevention strategies in the prostate: an overview.

Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED.

Rev Urol. 2002 Spring;4(2):69-77.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk